https://www.selleckchem.com/products/S31-201.html
68 vs. 3.13%, p = .008) and stroke (9.09 vs. 3.83%, p .001) than non-HBR patients at 4 years. There were no significant differences in BARC type 3 or 5 bleeding (3.07 vs. 2.76%, p = 1.0 or NACE rate (31.9 vs. 33.8%, p = .72) between patients who underwent 6- and 12-month DAPT. HBR patients are at a higher risk of long-term bleeding and ischemic events than non-HBR patients. The safety and efficacy of 6- and 12-month DAPT were comparable in HBR patients. HBR patients are at a higher risk of long-term bleeding and ischemic events t
Like
Comment
Share
